07/02/08, Cardiology/Hematology Bayer HealthCare acquires hematology development portfolio featuring MAXY-VII from Maxygen Phase 1 clinical testing expected to commence in third quarter of 2008 / Transaction includes license to Maxygen’s novel biotechnology research platform External Link: more
06/30/08, Research & Development Rivaroxaban is First Novel Oral Anticoagulant to Significantly Reduce the Composite Outcome of Symptomatic VTE and Death Rivaroxaban shows superior efficacy to enoxaparin for this clinical outcome with a comparable safety profile / Pre-specified analysis of pooled data from RECORD 1-3 studies involving nearly 10,000 pa... External Link: more